The clinical development candidate CCT245737 is an orally active CHK1 inhibitor with preclinical activity in RAS mutant NSCLC and Eμ-MYC driven B-cell lymphoma. The gene discussed is MYC; the disease is B-cell non-Hodgkin lymphoma.